National’s pitch is simple. Take money spent on aid projects most New Zealanders have never heard of and spend it on medicines they can see. The party wants to lift Pharmac’s medicines budget by $604 million, funded largely by a 10% cut to foreign aid outside the Pacific.
As health policy, it has real merit. As trade policy, nobody has done the accounting. Aid outside the Pacific is not charity in the way the campaign framing implies. For a small trading nation, it is often the cheapest market-entry tool available.
A bigger cheque for medicines
The health case is substantial. Pharmac’s 2026/27 medicines budget sits at $1.806 billion, so $604m over the forecast period is a meaningful lift in purchasing power for an agency that has been criticised for years over slow access to new cancer drugs.
The funding is less tidy than the photo opportunity suggests. The Pharmac uplift costs $151 million a year, against aid savings of $107.8 million a year. That leaves roughly $43m a year to be found elsewhere before the wider health package is even counted. A further 2% efficiency cut across MFAT is meant to save $45.6 million, and National points out that the ministry’s budget has nearly doubled since 2017. That is a fair target. A ministry that has grown that fast should be able to find 2% without losing much.
The cut lands on the growth markets
The aid cut is a different matter. The International Development Cooperation line in Vote Foreign Affairs is $1,111 million for 2026/27. Pacific aid makes up most of that and is fully protected, so the entire saving comes out of what is left. Newsroom’s analysis puts it at roughly a third of non-Pacific development spending, hitting Timor-Leste, Indonesia, Afghanistan and Ukraine among others.
That matters because Africa, Latin America and South-East Asia are where New Zealand’s export diversification has to happen if the country wants to reduce its reliance on China and Australia. Christopher Luxon’s example of waste, indigenous farmer workshops in Patagonia, plays well at a press conference. It also points to the very continent where Kiwi agritech and education exporters are looking for growth.
Massey University associate professor Gerard Prinsen, an aid and development specialist, called the plan “a bad idea in terms of geopolitical and business interests”. He notes that New Zealand funds more than 40 UN bodies, that Africa already gets under 1% of the aid budget, and that Africa’s population will be the world’s third largest within a decade. His warning is blunt. Without aid-based relationships, New Zealand risks becoming “a small island in the Pacific that maybe looks good on the tourist folder, but that’s about it.”
That is overstated. New Zealand’s trade access rests mostly on FTAs, not on development grants. But the core point holds. Trade negotiators and exporters rely on the networks, goodwill and access that aid programmes build, and competitors such as China, the EU and the UK are not cutting their soft-power spending in these regions.
A coalition fault line before the votes are counted
The most telling criticism comes from inside the likely government. Foreign Affairs Minister Winston Peters called the policy dangerous and desperate, saying “it is irresponsible for National to jeopardise the relationships we have in the very markets we need to grow our economy.” Peters is not an aid activist. He is the minister who has spent this term running MFAT as a trade-and-influence machine, and he is describing the cut as a hit to economic growth.
ACT’s David Seymour, who holds the Pharmac portfolio, welcomed it as “a great sign for the next coalition.” So National’s flagship health funding source now depends on settling an argument between its two most likely partners. Businesses should treat the policy as an opening bid, not a settled line in a future Budget.
What business should want answered
National is entitled to argue that New Zealanders’ health should come before workshops in Patagonia. That is a legitimate fiscal choice, and a centre-right government should scrutinise every line of a ministry budget that has doubled in under a decade.
What is missing is an honest account of the trade-off. If the cut goes ahead, which bilateral programmes in Kenya, Nigeria, Indonesia or Colombia close? Which UN forums does New Zealand step back from? How does MFAT plan to support exporters in markets where it is withdrawing development presence? Without those answers, voters are asked to compare tangible cancer drugs with an abstract cost that exporters will only notice once the relationships are gone.
Faster access to medicines is worth paying for. National should be clear that exporters may be the ones paying.
Sources
- NZ Herald: Election 2026 – National coming for Ministry of Foreign Affairs and Trade, foreign aid to pay for health policies (2026-10-05)
- 1News: National says it will cut foreign aid to boost Pharmac medicines budget (2026-10-06)
- Pharmac: 2026-27 Statement of Performance Expectations (2026)
- The Post: National pledges to lift Pharmac medicines budget by $604m by reducing foreign aid (2026-10-05)
- Budget 2026: Vote Foreign Affairs – Estimates of Appropriations 2026/27 (2026)
- Newsroom: Would Nats’ retreat on overseas aid make NZ great again? ‘NZ is already great’ (2026-10-06)
- RNZ: National’s proposed foreign aid cut could make NZ ‘invisible’ on world stage – expert (2026-10-07)
- RNZ: NZ First calls National’s foreign aid cut promise desperate, ACT hails it as win (2026-10-06)
Join the discussion
Add useful context, ask a good question, or challenge an idea — keep it specific and respectful.